Brief: Mustang Bio Provides An Update On Its Ind Application For Mb-207, A Lentiviral Gene Therapy For Treatment Of X-Linked Severe Combined Immunodeficiency (“Xscid”) In Previously Transplanted Patients

Mustang Bio

24/01/2022 22:07

Jan 24 (Reuters) - Mustang Bio Inc  MBIO.O :
    * MUSTANG BIO PROVIDES AN UPDATE ON ITS IND APPLICATION FOR
MB-207, A LENTIVIRAL GENE THERAPY FOR TREATMENT OF X-LINKED
SEVERE COMBINED IMMUNODEFICIENCY (“XSCID”) IN PREVIOUSLY
TRANSPLANTED PATIENTS
    * MUSTANG BIO INC -  U.S. FDA HAS ISSUED A HOLD, PENDING CMC
CLEARANCE, ON IND APPLICATION FOR MB-207
    * MUSTANG BIO INC - EXPECTS TO INITIATE A PHASE 2 CLINICAL
TRIAL
OF MB-107 UNDER A MUSTANG-SPONSORED IND IN NEWLY DIAGNOSED
INFANTS WITH XSCID IN Q3
    * MUSTANG BIO - BELIEVE CMC TEAM IS WELL POSITIONED TO
ADDRESS
FDA'S CONCERNS AROUND MB-207 ONCE ADDITIONAL CLARIFICATION OF
HOLD BECOMES AVAILABLE
    * MUSTANG BIO - ADDITIONALLY, EMA GRANTED ADVANCED THERAPY
MEDICINAL PRODUCT CLASSIFICATION, ORPHAN DRUG AND PRIME
DESIGNATION TO MB-107

Source text for Eikon:  ID:nGNX9Nk6QW 
Further company coverage:  MBIO.O 

 ((Reuters.Briefs@thomsonreuters.com;))